Outcomes and toxicities after axi-cel in the mITT cohort
| Covariate . | Before PS matching . | After PS matching . | ||||
|---|---|---|---|---|---|---|
| No BT, N = 132 . | BT, N=143 . | P value . | No BT, N = 97 . | BT, N = 97 . | P value . | |
| CRS grade ≥3 | 5% | 8% | .35 | 6% | 7% | >.99 |
| CRES/ICANS grade ≥3 | 27% | 34% | .2 | 28% | 32% | .64 |
| Need for G-CSF | 33% | 48% | .01 | 32% | 42% | .18 |
| ICU admission | 23% | 42% | .001 | 25% | 37% | .09 |
| Mean duration of hospital stay (d) | 15.7 | 18.5 | .04 | 16 | 18 | .33 |
| Covariate . | Before PS matching . | After PS matching . | ||||
|---|---|---|---|---|---|---|
| No BT, N = 132 . | BT, N=143 . | P value . | No BT, N = 97 . | BT, N = 97 . | P value . | |
| CRS grade ≥3 | 5% | 8% | .35 | 6% | 7% | >.99 |
| CRES/ICANS grade ≥3 | 27% | 34% | .2 | 28% | 32% | .64 |
| Need for G-CSF | 33% | 48% | .01 | 32% | 42% | .18 |
| ICU admission | 23% | 42% | .001 | 25% | 37% | .09 |
| Mean duration of hospital stay (d) | 15.7 | 18.5 | .04 | 16 | 18 | .33 |
CRES, CAR-related encephalopathy syndrome.